| Name | Title | Contact Details |
|---|
GeneSolve is the world’s first dedicated body chemistry company, with offices in the San Francisco Bay Area and Dallas, Texas. GeneSolve doctors utilize extensive laboratory tests and genetic analysis to provide personalized preventative health care programs to individual patients, as well as to groups through corporate wellness programs.
Valir Health is a comprehensive healthcare organization specializing in a full range of medical services. Our entities include a physical rehabilitation hospital, 15 physical therapy clinics, a hospice division, a fitness center, (PACE) a Program of All-inclusive Care for the Elderly, acupuncture clinic, corporate health and safety services and programs, and medical consulting and billing services. Valir Health provides uncompromised service to each patient and client we serve, we are committed to establishing a higher standard through strength, courage, and character. Driven by our motto, "Do the right thing," Valir has continued to grow through positive physician and patient referrals and strong business relationship development.
Clinaero is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive technique utilizes the company's proprietary TX MicroTip™ handpiece to cut and debride diseased tissue in an outpatient setting in under 20 minutes, using only a local anesthetic. Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.